Abecma, Breyanzi, CARVYKTI, Kymriah, Tecartus, Yeskarta
Human-Substructio CAR T Cell Therapy: Breakthroughs et provocationes
Introductio In regione oncologiae, immunotherapyae quasi methodologiae auctoris emersit, parat immunem corporis systema ad tumores malignos pugnandi. Multae accessiones immunotherae, sed Chimeric Antigen Rece.
Breyanzi, Iuno Therapeutica, B-Large Lymphom, LBCL, TRANSFERO
Lisocabtagena maraleucel a FDA approbatur pro curatio secunda linea lymphoma B-cellularum magnarum.
Iulii 2022: Lisocabtagene maraleucel (Breyanzi, Juno Therapeutica, Inc.) approbata est ab Administratione Cibus et medicamentis adultis aegris cum magna lymphoma B-cell (LBCL) qui refractorium morbum in primo-linea chemoi habent.
BMS, Breyanzi, Car - T Cell Lorem, CAR T-, Lorem CART, USFDA
Breyanzi - T-Lorem a Novus Car BMS
Iulii 2021: Breyanzi (Lisocabtagene maraleucel; liso-cel), nova CD19-receptor chimaerica directa (CAR) T curatio cellulae a Myers Squibb (BMS), a Cibus et medicamentis Administrationis US approbata est (US.